Search Result

Results for "

Glucagon+Receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenylate Cyclase (1) Cytochrome P450 (2) Endogenous Metabolite (1) GCGR (41) GLP Receptor (10) p38 MAPK (1) Reference Standards (2)
By Research Areas:	Endocrinology (1) Metabolic Disease (43)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Recombinant Proteins

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P3506

Retatrutide 3 Publications Verification LY3437943	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) is a triple agonist peptide of *the glucagon receptor* (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC₅₀** values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .

HY-P3375

Mazdutide IBI-362; LY-3305677; OXM-3	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D) .

HY-50663

MK 0893 Maximum Cited Publications 6 Publications Verification	GCGR	Metabolic Disease
MK 0893 is a potent and selective *glucagon receptor* antagonist with an IC₅₀ of 6.6 nM.

HY-19904

Adomeglivant 4 Publications Verification LY2409021	GCGR	Metabolic Disease
Adomeglivant (LY2409021) is a potent, selective glucagon receptor (GluR) allosteric antagonist. Adomeglivant is widely used in the research for type 2 diabetes mellitus .

HY-P3506A

Retatrutide TFA 3 Publications Verification LY3437943 TFA	GLP Receptor GCGR	Metabolic Disease
Retatrutide (LY3437943) TFA is a triple agonist peptide of *the glucagon receptor* (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC₅₀** values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .

HY-19947

PF-06291874 1 Publications Verification Glucagon receptor antagonists-4	GCGR	Metabolic Disease
PF-06291874 is a highly potent, non-peptide and orally active *glucagon receptor* antagonist. PF-06291874 is under the study for type 2 diabetes mellitus (T2DM) .

HY-12525

LGD-6972	GCGR	Metabolic Disease
LGD-6972 is a selective and orally active *glucagon receptor* antagonist. LGD-6972 has the potential for type 2 diabetes research .

HY-P99357

Crotedumab REGN1193; Anti-GCGR Reference Antibody (crotedumab)	GCGR	Metabolic Disease
Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a K_D of 0.1 nM. Crotedumab can be used for the research of diabetes .

HY-124622

NNC-0640	GCGR	Metabolic Disease
NNC-0640 is an effective negative allosteric modulator (NAM) of the human glucagon receptor (GCGR), with an IC₅₀ value of 69.2 nM. NNC-0640 holds potential for research in the field of diabetes .

HY-P3375A

Mazdutide TFA IBI-362 TFA; LY-3305677 TFA; OXM-3 TFA	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) TFA is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide TFA binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide TFA is used in studies of obesity and type 2 diabetes (T2D) .

HY-103547

L-168049 1 Publications Verification	GCGR	Metabolic Disease
L-168049 is a potent, selective, orally active and non-competitive *glucagon receptor* antagonist with IC₅₀s of 3.7 nM, 63 nM, and 60 nM for human, murine, and canine glucagon receptors, respectively .

HY-50675

GRA Ex-25	GCGR	Metabolic Disease
GRA Ex-25 is an inhibitor of *glucagon receptor, with IC₅₀* of 56 and 55 nM for rat and human glucagon receptors, respectively.

HY-P99383

Volagidemab REMD-477; AMG-477	GCGR	Metabolic Disease
Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D) .

HY-50159

Glucagon receptor antagonist-3	GCGR	Metabolic Disease
Glucagon receptor antagonist-3 is a highly potent glucagon receptor antagonist.

HY-148844

GCGR antagonist 2	GCGR	Metabolic Disease
GCGR antagonist 2, a Furan-2-carbohydrazide, is an orally active *glucagon receptor* antagonist. GCGR antagonist 2 binds to hGluR with an K_d value of 2.3 nM, and inhibits rat receptor with an IC₅₀ value of 0.43 nM. GCGR antagonist 2 inhibits glucagon-stimulated glycogenolysis .

HY-P10018

Bamadutide SAR425899	GLP Receptor GCGR	Metabolic Disease
Bamadutide (SAR425899) is a potent dual glucagon-like peptide-1 receptor/glucagon receptor (GLP-1R/GCGR) agonist. Bamadutide improves post-meal blood glucose control by significantly enhancing β-cell function and slowing down the rate of glucose absorption in the body. Bamadutide can be used for the research of metabolic diseases such as type 2 diabetes .

HY-10036

Glucagon receptor antagonist-1	GCGR	Metabolic Disease
Glucagon receptor antagonist-1 is a highly potent glucagon receptor antagonist.

HY-50158

Glucagon receptor antagonist-2	GCGR	Metabolic Disease
Glucagon receptor antagonist-2 is a highly potent glucagon receptor antagonist.

HY-P10032

NN1177 NNC9204-1177	GCGR GLP Receptor Cytochrome P450	Metabolic Disease
NN1177 is a long-acting **GLP-1/glucagon receptor** co-agonist. NN1177 can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice .

HY-P1143A

*[Des-His1,Glu9]-Glucagon* amide TFA**	GCGR	Metabolic Disease
[Des-His1,Glu9]-Glucagon amide TFA is a potent and peptide antagonist of the *glucagon receptor, with a pA₂* of 7.2. [Des-His1,Glu9]-Glucagon amide TFA is potentially useful in the study of the pathogenesis of diabetes .

HY-128781

Glucagon receptor antagonist-5	GCGR	Metabolic Disease
Glucagon receptor antagonist-5 (compound 13K) is a potent and orally bioavailable indazole-based *glucagon receptor* antagonist (K_i=32 nM). Glucagon receptor antagonist-5 has potential for the treatment of type 2 diabetes mellitus (T2DM) .

HY-P1143

*[Des-His1,Glu9]-Glucagon* amide**	GCGR	Metabolic Disease
[Des-His1,Glu9]-Glucagon amide is a potent and peptide antagonist of the *glucagon receptor, with a pA₂* of 7.2. [Des-His1,Glu9]-Glucagon amide is potentially useful in the study of the pathogenesis of diabetes .

HY-P3506B

Retatrutide acetate LY3437943 acetate	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) acetate is a triple agonist peptide of *the glucagon receptor* (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC₅₀** values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity .

HY-19374

BAY-27-9955	GCGR	Metabolic Disease
BAY-27-9955 is an orally active non-peptide *glucagon receptor* antagonist. Bay 27-9955 competitively blocks the interaction of glucagon with the human glucagonreceptor at an IC₅₀ value of 110 nM. BAY-27-9955 can be used for the study of type 2 diabetes .

HY-P10965

Zovaglutide ZT002	GLP Receptor	Metabolic Disease
Zovaglutide (ZT002) is a long-acting, selective GLP-1 receptor agonist. Zovaglutide enhances albumin binding capacity via dual fatty acid chain modification. Zovaglutide exerts metabolic effects through central and peripheral GLP-1 pathways, thereby promoting satiety, reducing caloric intake and enhancing glucose-dependent insulin secretion, with no activity against GIP or glucagon receptors. Zovaglutide can be used in research on type 2 diabetes or obesity .

HY-107129

MK-3577	GCGR	Metabolic Disease
MK-3577 is an orally effective glucagon receptor (GCGR) antagonist that reduces hepatic glucose production and lowers blood glucose levels by blocking glucagon receptors on target organs, primarily the liver. Pharmacokinetic analysis in domestic cats indicates that MK-3577 reaches peak levels 3 to 4 hours after oral administration, with a half-life of approximately 15 hours. MK-3577 can be used in diabetes research .

HY-118914

Glucagon receptor antagonist inactive control	GCGR
Glucagon receptor antagonist inactive control (Compound 2) is a compound structurally similar to the glucagon receptor (GCGR) antagonist Glucagon receptor antagonist (Compound 1) but lacks antagonistic activity against glucagon receptor (GCGR). Glucagon receptor antagonist inactive control can be used as a negative control to study mechanisms related to glucagon receptor-mediated signaling pathways .

HY-116854

NNC 92-1687	GCGR	Metabolic Disease
NNC 92-1687 is a non-peptide competitive human *glucagon receptor* antagonist (IC₅₀=20 μM; K_i=9.1 μM). NNC 92-1687 can be used in the research of type 2 diabetes .

HY-128103

Glucagon receptor antagonist-7	GCGR Adenylate Cyclase	Metabolic Disease
Glucagon receptor antagonist-7 (Compound 1) is an antagonist for hGCGR, that inhibits the binding of 125I-labeled glucagon to the human glucagon receptor (hGCGR) with IC₅₀ of 181 nM. Glucagon receptor antagonist-7 activates glucagon-stimulated adenylyl cyclase with a K_DB of 81 nM in CHO cell. Glucagon receptor antagonist-7 inhibits glucagon-mediated glycogenolysis in human hepatocytes, and lowers blood glucose levels .

HY-169707

GCGR antagonist 3	GCGR	Metabolic Disease
GCGR antagonist 3 (example 1) is an antagonist of the glucagon receptor (GCGR) and can be used in diabetes research .

HY-12525A

LGD-6972 sodium	GCGR	Metabolic Disease
LGD-6972 sodium is a selective and orally active *glucagon receptor* antagonist. LGD-6972 sodium has the potential for type 2 diabetes research .

HY-P10327

PP18	GLP Receptor	Metabolic Disease
PP18 is a novel OXM-based dual GLP-1 and glucagon receptor agonist with EC₅₀ values of 0.487 nM target hGLP-1R and 0.188 nM target hGcgR .

HY-180446

Glucagon receptor antagonist-11	GCGR	Metabolic Disease
Glucagon receptor antagonist-11 (Compound 14) is a *glucagon receptor* antagonist with a pIC₅₀ of 6.677. Glucagon receptor antagonist-10 can be used in studies of glucose homeostasis .

HY-180445

Glucagon receptor antagonist-10	GCGR	Metabolic Disease
Glucagon receptor antagonist-10 (Compound 11) is a *glucagon receptor* antagonist with a pIC₅₀ of 7.154. Glucagon receptor antagonist-10 can be used in studies of glucose homeostasis .

HY-19904R

Adomeglivant (Standard) LY2409021 (Standard)	GCGR Reference Standards	Metabolic Disease
Adomeglivant (Standard) is the analytical standard of Adomeglivant. This product is intended for research and analytical applications. Adomeglivant (LY2409021) is a potent, selective glucagon receptor (GluR) allosteric antagonist. Adomeglivant is widely used in the research for type 2 diabetes mellitus .

HY-12735

SCH 900822	GCGR	Metabolic Disease Endocrinology
SCH 900822 is a potent and selective glucagon receptor (hGCGR) antagonist that blocks the binding of glucagon to its receptor, thereby reducing hepatic glycogenolysis and gluconeogenesis, thereby lowering blood glucose production. SCH 900822 can be used in the study of type 2 diabetes .

HY-180444

Glucagon receptor antagonist-9	GCGR	Metabolic Disease
Glucagon receptor antagonist-9 (compound 13) is a potent *glucagon receptor* antagonist with a pIC₅₀ of 7.000 .

HY-P10032A

NN1177 TFA NNC9204-1177 TFA	GCGR Cytochrome P450 GLP Receptor	Metabolic Disease
NN1177 (NNC9204-1177) TFA is a long-acting **GLP-1/glucagon receptor** co-agonist. NN1177 TFA can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice .

HY-P3608

[Des-His1,Glu9] Glucagon	GCGR	Metabolic Disease
[Des-His1,Glu9] Glucagon is a potent glucagon receptor system peptide antagonist. [Des-His1,Glu9] Glucagon enhances the glucose-stimulated release of insulin from pancreatic islet cells. [Des-His1,Glu9] Glucagon can be used to research diabetes .

HY-177156

Glucagon receptor antagonist-8	GCGR p38 MAPK	Metabolic Disease
Glucagon receptor antagonist-8 (Compound 1) is a human glucagon receptor and p38 mitogen-activated protein (MAP) kinase antagonist, with IC₅₀s of 0.27 μM and 0.16 μM, respectively .

HY-19904A

(+/-)-Adomeglivant (+/-)-LY2409021	Endogenous Metabolite	Metabolic Disease
(+/-)-Adomeglivant ((+/-)-LY2409021) is a potent and selective glucagon receptor antagonist with hypoglycemic activity. (+/-)-Adomeglivant is effective in lowering blood sugar levels in both healthy people and people with type 2 diabetes. (+/-)-Adomeglivant is well tolerated by glucagon signaling blockade in patients with type 2 diabetes and significantly reduces fasting and postprandial blood glucose with a concomitant reversible elevation of aminotransferases. Glucagon signaling inhibition by (+/-)-Adomeglivant is a promising potential inhibitory approach for patients with type 2 diabetes and warrants further evaluation of its benefits and risks in longer clinical trials .

HY-103547R

L-168049 (Standard)	Reference Standards GCGR	Metabolic Disease
L-168049 (Standard) is the analytical standard of L-168049 (HY-103547). This product is intended for research and analytical applications. L-168049 is a potent, selective, orally active and non-competitive glucagon receptor antagonist with IC₅₀s of 3.7 nM, 63 nM, and 60 nM for human, murine, and canine glucagon receptors, respectively .

HY-12525B

LGD 6972 ammonium	GCGR	Metabolic Disease
LGD-6972 ammonium is a selective and orally active *glucagon receptor* antagonist. LGD-6972 ammonium has the potential for type 2 diabetes research .

HY-P992007

PF-06293620 RN909	GCGR	Metabolic Disease
PF-06293620 (RN909) is a monoclonal antibody antagonist of the *glucagon receptor*. PF-06293620 produces dose-dependent, durable lowering of fasting plasma glucose and reduces HbA1c levels. PF-06293620 can be used for the research of type 2 diabetes mellitus .

Cat. No.	Product Name

HY-L040

Anti-diabetic Compound Library	1,113 compounds
Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage. The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes. MCE Anti-diabetic Compound Library owns a unique collection of 1,113 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Anti-diabetic Compound Library

1,113 compounds

Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage.

The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes.

MCE Anti-diabetic Compound Library owns a unique collection of 1,113 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Cat. No.	Product Name	Target	Research Area

HY-P3506

Retatrutide 3 Publications Verification LY3437943	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) is a triple agonist peptide of *the glucagon receptor* (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC₅₀** values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .

HY-P3375

Mazdutide IBI-362; LY-3305677; OXM-3	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D) .

HY-P3506A

Retatrutide TFA 3 Publications Verification LY3437943 TFA	GLP Receptor GCGR	Metabolic Disease
Retatrutide (LY3437943) TFA is a triple agonist peptide of *the glucagon receptor* (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC₅₀** values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .

HY-P3375A

Mazdutide TFA IBI-362 TFA; LY-3305677 TFA; OXM-3 TFA	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) TFA is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide TFA binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide TFA is used in studies of obesity and type 2 diabetes (T2D) .

HY-P10018

Bamadutide SAR425899	GLP Receptor GCGR	Metabolic Disease
Bamadutide (SAR425899) is a potent dual glucagon-like peptide-1 receptor/glucagon receptor (GLP-1R/GCGR) agonist. Bamadutide improves post-meal blood glucose control by significantly enhancing β-cell function and slowing down the rate of glucose absorption in the body. Bamadutide can be used for the research of metabolic diseases such as type 2 diabetes .

HY-P10032

NN1177 NNC9204-1177	GCGR GLP Receptor Cytochrome P450	Metabolic Disease
NN1177 is a long-acting **GLP-1/glucagon receptor** co-agonist. NN1177 can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice .

HY-P1143A

*[Des-His1,Glu9]-Glucagon* amide TFA**	GCGR	Metabolic Disease
[Des-His1,Glu9]-Glucagon amide TFA is a potent and peptide antagonist of the *glucagon receptor, with a pA₂* of 7.2. [Des-His1,Glu9]-Glucagon amide TFA is potentially useful in the study of the pathogenesis of diabetes .

HY-P1143

*[Des-His1,Glu9]-Glucagon* amide**	GCGR	Metabolic Disease
[Des-His1,Glu9]-Glucagon amide is a potent and peptide antagonist of the *glucagon receptor, with a pA₂* of 7.2. [Des-His1,Glu9]-Glucagon amide is potentially useful in the study of the pathogenesis of diabetes .

HY-P3506B

Retatrutide acetate LY3437943 acetate	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) acetate is a triple agonist peptide of *the glucagon receptor* (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC₅₀** values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity .

HY-P10965

Zovaglutide ZT002	GLP Receptor	Metabolic Disease
Zovaglutide (ZT002) is a long-acting, selective GLP-1 receptor agonist. Zovaglutide enhances albumin binding capacity via dual fatty acid chain modification. Zovaglutide exerts metabolic effects through central and peripheral GLP-1 pathways, thereby promoting satiety, reducing caloric intake and enhancing glucose-dependent insulin secretion, with no activity against GIP or glucagon receptors. Zovaglutide can be used in research on type 2 diabetes or obesity .

HY-P10327

PP18	GLP Receptor	Metabolic Disease
PP18 is a novel OXM-based dual GLP-1 and glucagon receptor agonist with EC₅₀ values of 0.487 nM target hGLP-1R and 0.188 nM target hGcgR .

HY-P10032A

NN1177 TFA NNC9204-1177 TFA	GCGR Cytochrome P450 GLP Receptor	Metabolic Disease
NN1177 (NNC9204-1177) TFA is a long-acting **GLP-1/glucagon receptor** co-agonist. NN1177 TFA can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice .

HY-P3608

[Des-His1,Glu9] Glucagon	GCGR	Metabolic Disease
[Des-His1,Glu9] Glucagon is a potent glucagon receptor system peptide antagonist. [Des-His1,Glu9] Glucagon enhances the glucose-stimulated release of insulin from pancreatic islet cells. [Des-His1,Glu9] Glucagon can be used to research diabetes .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99357

Crotedumab REGN1193; Anti-GCGR Reference Antibody (crotedumab)	GCGR	Metabolic Disease
Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a K_D of 0.1 nM. Crotedumab can be used for the research of diabetes .

HY-P99383

Volagidemab REMD-477; AMG-477	GCGR	Metabolic Disease
Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D) .

HY-P992007

PF-06293620 RN909	GCGR	Metabolic Disease
PF-06293620 (RN909) is a monoclonal antibody antagonist of the *glucagon receptor*. PF-06293620 produces dose-dependent, durable lowering of fasting plasma glucose and reduces HbA1c levels. PF-06293620 can be used for the research of type 2 diabetes mellitus .

Recombinant Proteins Recommended:

Glucagon Receptor

Species:	Human (6) Rat (1) Mouse (1)
Tag:	His (5) Tag Free (1) Avi (2) Myc (1) Fc (2)
Source:	HEK293 (8)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P78702

	*GCGR/Glucagon receptor* Protein, Mouse (HEK293, Fc)** Glucagon R; GCGR; Glucagon receptor	Mouse	HEK293
	GCGR/glucagon receptor protein is a G protein-coupled receptor for glucagon that centrally regulates blood glucose levels. It plays a key role in the fasting response by actively regulating hepatic glucose production by promoting glycogen hydrolysis and gluconeogenesis. GCGR/Glucagon receptor Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived GCGR/Glucagon receptor protein, expressed by HEK293 , with C-hFc labeled tag. The total length of GCGR/Glucagon receptor Protein, Mouse (HEK293, Fc) is 111 a.a., with molecular weight of 50-65 kDa.

HY-P705976

	GCGR Protein, Rat (HEK293, His) Glucagon receptor; GL-R; Gcgr	Rat	HEK293

HY-P703987

	GCGR Protein, Human (HEK293, His, Avi) Glucagon receptor; GL-R; GCGR; Glucagon R	Human	HEK293
	The GCGR protein is a glucagon G protein-coupled receptor that is critical in blood glucose regulation and actively controls hepatic glucose production. It promotes glycogen hydrolysis and gluconeogenesis, which are critical for the fasting response. GCGR Protein, Human (HEK293, His, Avi) is the recombinant human-derived GCGR protein, expressed by HEK293, with C-Avi and C-His labeled tag.

HY-P703992

	GCGR Protein, Human (HEK293, hFc) Glucagon receptor; GL-R; GCGR; Glucagon R	Human	HEK293
	The GCGR protein is a glucagon G protein-coupled receptor that is critical in blood glucose regulation and actively controls hepatic glucose production. It promotes glycogen hydrolysis and gluconeogenesis, which are critical for the fasting response. GCGR Protein, Human (HEK293, hFc) is the recombinant human-derived GCGR protein, expressed by HEK293, with C-hFc labeled tag.

HY-P704627

	GCGR Protein-VLP, Human (HEK293) glucagon receptor; GGR; GL-R; FLJ97182; MGC138246;	Human	HEK293
	GCGR Protein-VLP, Human (HEK293) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P705433.

HY-P704626

	GCGR Protein, Human (HEK293, His) glucagon receptor; GGR; GL-R; FLJ97182; MGC138246;	Human	HEK293
	The GCGR protein is a glucagon G protein-coupled receptor that is critical in blood glucose regulation and actively controls hepatic glucose production. It promotes glycogen hydrolysis and gluconeogenesis, which are critical for the fasting response. GCGR Protein, Human (HEK293, His) is the recombinant human-derived GCGR protein, expressed by HEK293, with C-His labeled tag.

HY-P705157

	GCGR Protein, Human (Biotinylated, HEK293, His-Avi) glucagon receptor; GGR; GL-R; FLJ97182; MGC138246;	Human	HEK293

HY-P700411

	GCGR Protein, Human (HEK293, N-His, C-Myc) glucagon receptor; GGR; GL-R; FLJ97182; MGC138246;	Human	HEK293
	The GCGR protein is a glucagon G protein-coupled receptor that is critical in blood glucose regulation and actively controls hepatic glucose production. It promotes glycogen hydrolysis and gluconeogenesis, which are critical for the fasting response. GCGR Protein, Human (HEK293, N-His, C-Myc) is the recombinant human-derived GCGR protein, expressed by HEK293 , with C-Myc, N-10*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: